RxDoctor Payments DataLook up a doctor →

Richard Dolinar, MD

Endocrinology · Phoenix, AZNPI 1548227028

Payments from drug & device makers

$411,040in general payments, 2019–2025

Across 759 payments — averaging $541.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$343K
  • Novo Nordisk$37K
  • Boehringer Ingelheim$17K
  • AstraZeneca$7K
  • Medtronic$2K
  • Tandem Diabetes Care, Inc.$2K
  • plus $4K from 17 others

What the payments were for

  • Consulting fees$6,8852%
  • Speaking & faculty fees$368,48890%
  • Travel & lodging$24,6976%
  • Food & beverage$10,7193%
  • Education$1920%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few endocrinology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$114,028
Medicare patients
197
Services billed
3,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide280$420,212
TrulicityDulaglutide257$408,523
JardianceEmpagliflozin269$353,560
MounjaroTirzepatide191$280,585
FarxigaDapagliflozin Propanediol94$102,637
Tresiba Flextouch U-100Insulin Degludec98$56,234
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$32,407
Fiasp FlextouchInsulin Aspart (Niacinamide)17$27,212
Humalog Kwikpen U-100Insulin Lispro102$25,440
Nano 2nd Gen Pen NeedlePen Needle, Diabetic135$21,900
Lantus SolostarInsulin Glargine,hum.Rec.Anlog130$21,695
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$16,820
LyumjevInsulin Lispro-Aabc11$16,568
Lyumjev Kwikpen U-100Insulin Lispro-Aabc15$15,929
Novolog FlexpenInsulin Aspart58$15,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Baqsimi, Humalog$342,888$718,472491 claims
Novo NordiskOzempic$36,664$420,212280 claims
Boehringer IngelheimJardiance$17,329$353,560269 claims
AstraZenecaFarxiga$6,555$102,63794 claims
AbbVieSynthroid$90$8,45761 claims
Sanofi-aventis U.S. LLCLantus$1,084$5,03315 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$41$1,517134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other endocrinology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →